Eli Lilly and Company does not intend to give up Trulicity (dulaglutide) market share to competitors’ glucagon-like peptide 1 (GLP-1) receptor agonists and it does not plan to shift patients from its blockbuster type 2 diabetes band to tirzepatide, if the dual agonist of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) is approved next year. Instead, the company hopes to grow the overall GLP-1 market, in part by increasing prescriptions in the drug class for patients earlier in their treatment.
Lilly executives explained during a 1 July investor event, which followed the American Diabetes Association’s (ADA’s) Scientific Sessions at the end of June, that the blood glucose reductions, weight loss and cardiovascular benefits observed in the Phase III SURPASS clinical trial program for tirzepatide justify earlier treatment with the dual incretin agonist to forestall diabetes and cardiovascular disease progression
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
